Hydrofarm Holdings Group, Inc. — Q3 2022 Form 10-Q
Business context and period: Hydrofarm manufactures and distributes controlled-environment agriculture equipment and supplies, principally in the U.S. and Canada. This unaudited report covers the three and nine months ended September 30, 2022; dollar amounts below are in millions unless stated otherwise.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Net sales | $74.2 | $123.8 | $283.0 | $369.0 |
| Gross profit / margin | $5.9 / 7.9% | $30.0 / 24.2% | $29.8 / 10.5% | $82.8 / 22.4% |
| Operating income (loss) | $(20.3) | $(2.4) | $(254.9) | $6.3 |
| Net income (loss) | $(23.5) | $17.3 | $(250.1) | $24.5 |
| Adjusted EBITDA (non-GAAP) | $(9.0) | $16.1 | $(12.8) | $42.2 |
| Operating cash flow | Not stated separately for Q3 | $15.5 | $(17.5) |
Balance sheet, cash flow and liquidity
- At September 30, cash and cash equivalents were $16.5, current assets $186.7 and current liabilities $48.7. Inventory was $137.0, down from $189.1 at December 31, 2021.
- Total debt was $120.9, including $118.7 of long-term debt and $2.1 current debt. The $124.1 term loan principal bears variable interest; its reported effective rate was 9.21% in Q3. The company had no revolver borrowings and reported approximately $62 available under its asset-based revolver.
- Nine-month operating cash flow of $15.5 reflected a $22.7 working-capital inflow, including inventory and receivables reductions, partly offset by lower accounts payable, accrued liabilities and deferred revenue. Investing used $7.4; financing used $19.5, including $15.6 to settle contingent consideration. Cash, cash equivalents and restricted cash declined by $11.9 to $16.5.
- Management said cash, operating cash flows and borrowing availability should fund operations, debt service and other needs for the next 12 months. It was also evaluating potential sale-leasebacks, asset sales or equity financing as liquidity supplements.
Material changes and notable items
- Q3 sales fell 40.1% year over year; nine-month sales fell 23.3%. Management attributed the declines mainly to lower sales volumes amid agricultural oversupply and weaker cannabis-growing activity. Q3 volume declined 42.6%, partly offset by higher price and mix.
- Gross margin contracted sharply. Management cited inventory obsolescence charges, especially for lighting products, and freight and labor costs that were higher relative to sales. Inventory-related charges and accounts-receivable allowances were $5.5 in Q3 and $18.9 for the nine months.
- Nine-month impairments totaled $192.3, including a $189.6 goodwill impairment that reduced goodwill to zero and a $2.6 impairment on a note receivable. The goodwill charge followed lower estimated reporting-unit values amid deteriorating demand and market conditions. No intangible-asset impairment was recorded.
- Inventory obsolescence allowances were $4.4 in Q3 and $17.8 for the nine months. Q3 also included a $1.1 increase in accounts-receivable allowances. Further write-downs or impairments remain possible.
- Interest expense rose substantially year over year, primarily because the term loan was outstanding throughout 2022. The company reported compliance with term-loan and revolver covenants at quarter-end.
Outlook, risks and contingencies
- No quantified sales, earnings or margin guidance was provided. Management said the duration and effects of industry conditions were uncertain. It reduced production, implemented workforce reductions or temporary furloughs, and was evaluating further operating streamlining, potentially including facility changes and a narrower product and brand portfolio.
- Key risks include continued oversupply and declining customer demand, inventory obsolescence and margin pressure, possible further asset impairments, customer credit losses, variable-rate debt and the availability of liquidity. The company also cited potential supply-chain disruption, foreign-exchange exposure, long-term lease obligations and regulatory uncertainty.
- A 100-basis-point increase in rates was estimated to raise annual interest expense by approximately $1.1. The company did not hedge its interest-rate exposure.
- Management said ordinary-course claims were not expected to have a material adverse effect. The filing reported no material legal proceedings, debt defaults or unregistered equity sales.
Important facts for investors to verify
- Whether sales volumes and demand stabilize, particularly in cannabis-related markets, and how performance compares after considering acquisitions.
- Whether inventory levels, lighting-product reserves, receivable allowances and gross margins improve or require further charges.
- Cash generation and liquidity headroom, including revolver borrowing-base availability, covenant triggers, and management’s stated 12-month funding assessment.
- Term-loan interest costs and the effects of variable rates, alongside debt service and lease commitments.
- Assumptions behind the goodwill impairment and the recoverability of $306.2 of intangible assets and other long-lived assets.